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Abstract
Background:  Most depressed patients are attended at primary care. However, there are
significant shortcomings in the diagnosis, management and outcomes of these patients. The aim of
this study is to determine whether the implementation of a structured programme for managing
depression will provide better health outcomes than usual management.
Methods/Design: Design: A cluster-randomized controlled trial involving two groups, one of
which is the control group consisting of patients who are treated for depression in the usual way
and the other is the intervention group consisting of patients on a structured programme for
treating depression.
Setting: 20 primary care centres in the province of Tarragona (Spain)
Sample: 400 patients over 18 years of age who have experienced an episode of major depression
(DSM-IV) and who need to initiate antidepressant treatment
Intervention: A multi-component programme with clinical, educational and organisational
procedures that includes training for the health care provider and evidence-based clinical
guidelines. It also includes primary care nurses working as care-managers who provide educational
and emotional support for the patients and who are responsible for active and systematic clinical
monitoring. The programme aims to improve the primary care/specialized level interface.
Measurements: The patients will be monitored by telephone interviews. The interviewer will not
know which group the patient belongs to (blind trial). These interviews will be given at 0, 3, 6 and
12 months.
Main variables: Severity of the depressive symptoms, response rate and remission rate.
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Analysis: Outcomes will be analyzed on an intent-to-treat basis and the unit of analysis will be the
individual patient. This analysis will take into account the effect of study design on potential lack of
independence between observations within the same cluster.
Discussion: The effectiveness of caring for depression in primary care can be improved by various
strategies. The most effective models involve organisational changes and a greater role of nurses.
However, these models are almost exclusively from the USA, and this randomized clinical trial will
determine if this approach could be effective to improve the outcomes of depression in primary
care in the Spanish health care system.
Trial registration: ISRCTN16384353
Background
Depressive disorders have been estimated to be the lead-
ing cause of disability (i.e. non-fatal burden) in the world
[1]. Primary health care, which is the health system's first
level of care, is the main ambit in which the most com-
mon mental disorders in the population are treatedf,
including depression, and the majority of patients suffer-
ing from depression are attended exclusively at this care
level [2]. However, it has been demonstrated that the
detection, diagnosis, treatment and monitoring of
patients with depression have significant shortcomings
with regard to the model that could be referred to as "the
best practice" [3].
In a recent study we found that 14.3% of consecutive pri-
mary care patients can be diagnosed with major depres-
sion according to DSM-IV criteria [4]. More than half of
the depressed patients presented only somatic symptoms
and were more difficult to detect by their primary care
doctors than patients who openly revealed the psycholog-
ical nature of their depression [5]. Furthermore, the fact
that depression was detected was no guarantee that the
patients would receive the appropriate treatment:
although 72% of people suffering from depression were
detected by their primary care doctor, only 34% received
specific treatment with antidepressants while 48% were
treated with anxiolytic or hypnotic drugs [6]. In primary
care, the rates of non-compliance or early discontinuation
of antidepressant prescriptions are high [7] and the evolu-
tion of the depressed patient once the treatment has been
established is often inadequately monitored, if at all.
Therefore, the opportunity to monitor therapeutic com-
pliance and clinical evolution, and to implement meas-
ures to improve adherence to the treatment or to adjust
inefficient treatments is lost. What is more, access to psy-
chotherapeutic treatment of proven effectiveness as a first
line therapy in certain types of mild or moderate depres-
sion within the ambit of primary care in the Spanish
health system is almost non-existent. Each of these factors
compromises the health outcomes that could be obtained
in a depressed patient, according to scientific evidence.
In its mental health strategy, the World Health Organisa-
tion rightly considers that in order to reduce the impact of
depression, in public health terms, the distance that exists
between the availability of potentially effective therapeu-
tic measures and the high proportion of depressed
patients who are unable to benefit from such options
must be overcome. A specific aim in this regard is to pro-
vide effective coverage for depression in primary care [8].
In order to improve the diagnosis and treatment of
depression in primary care and obtain high rates of effi-
ciency that are closer to the potential effectiveness of avail-
able treatments [9], certain strategies of an educational
and organisational nature have been proposed, including
the training of healthcare professionals, the availability of
clinical practice guidelines and strategies to implement
them, case management-allocating a central role to non-
medical professionals, often nurses-, and collaboration
between the primary care level and specialised psychiatric
level. The complex models that involve organisational
changes and a greater role for nurses rather than the
implementation of simple measures (i. e. medical educa-
tion or access to clinical guidelines as the only measures)
have been shown to be most effective [10-12]. The princi-
pal limitation of the existing research is that the studies
are almost exclusively from the United States, and this
raises the question of whether strategies that are effective
within one social context and health organisation can be
equally effective in other countries with different health-
care structures.
Methods/Design
Objectives
The general aim is to determine whether a programme for
treating depression leads to better health outcomes than
the usual depression management provided in primary
care in the Spanish healthcare system. The specific aims
are to determine whether the programme for treating
depression, compared to usual practice, will reduce the
severity of depression, and increase the response and
remission rates, and the degree of health-related quality of
life at 3, 6 and 12 months.BMC Public Health 2007, 7:253 http://www.biomedcentral.com/1471-2458/7/253
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Design
This is a controlled trial with a random allocation of clus-
ters (primary healthcare centres) in two alternative
branches (see Figure 1):
1. Usual management of depression (control group) and
2. Implementation of a programme to manage depression
(intervention group).
The evaluation of the treatment outcomes will be done at
patient level, evaluated individually [13].
Setting and study sample
All of the 20 primary healthcare centres in the Tarragona-
Reus Primary Care Area (Catalan Health Institute) in the
province of Tarragona, Catalonia, Spain, have agreed to
participate. The doctors from each centre who participated
in the study had to be full-time employees, remain in the
same location for the duration of the study and have a
quota of patients assigned.
The doctors participating in the study will ask all patients
who have suffered from an episode of major depression
(DSM-IV) and who have been advised to take a new
course of antidepressants to take part, until they reach
their assigned quota of patients.
Patients considered for inclusion are those assigned to the
doctor, aged ≥18 years, able to be contacted by telephone,
who have been diagnosed with an episode of major
depression (DSM-IV), have a score of >14 on the PHQ-9
(moderate-severe depression) or a score of 10 to 14 (mild
depression) that has persisted for more than one month,
and who have not received antidepressant medication in
the previous three months.
The following patients will be excluded: those who suffer
from physical, psychiatric or linguistic limitations or a
concurrent illness that impede comprehension/participa-
tion in the study evaluations, patients with psychotic or
bipolar disorders, patients with alcohol or drug depend-
ence and patients who are pregnant or breastfeeding.
Flowchart: randomisation of centres, and sampling and monitoring of patients Figure 1
Flowchart: randomisation of centres, and sampling and monitoring of patients.
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Allocation of study groups
In order to ensure comparability between the intervention
group and the control group, each centre will be paired
with another centre with similar features [13]: urban/rural
location, the number of participating doctors and the
availability of a psychiatrist in the own centre. One of
each pair of centres will be randomly allocated as a treat-
ment or a control centre. The pairing and the allocation
will be carried out by an independent person not involved
in the study.
The centres agree to participate before the random alloca-
tion. The patients agree to participate without knowing to
which study group their centre has been allocated.
Intervention
The intervention consists of a multi-component pro-
gramme that deals with depression based on published
scientific evidence. It includes measures that can be rea-
sonably applied within the Spanish health organisation.
Such actions are of a clinical, training-based, organisa-
tional and health-related educational nature.
The programme includes tools for the systematic and
structured evaluation and treatment of depression in pri-
mary care. There is an initial 8-hour course based on the
clinical guidelines for treating depression recommended
by the National Institute for Health and Clinical Excel-
lence (NICE) [14] and designed to improve doctors'
knowledge and skills in diagnosing depression, evaluating
suicidal risk, clinical treatment, monitoring depression,
and modifying the therapy in order to achieve remission
in accordance with a treatment algorithm. The training
puts the emphasis on the care procedure, active clinical
monitoring of depressed patients and the options availa-
ble when the proposed aims are not achieved (short-term
remission and no relapse in the long term). The educa-
tional plan includes periodic updates.
A Depression Management Toolkit that contains a treat-
ment algorithm for optimizing the prescription of antide-
pressant medication is available for the participating
doctors.
The programme creates the role of case managers. The case
managers are nurses on the staff of the participating pri-
mary care centres with specific training (a 8-hour initial
course plus periodic updates) in the clinical aspects of
depression, antidepressant treatment, secondary effects,
treatment adherence and the methods to ensure this,
warning signs in the evolution of depression, etc. The
case-manager identifies individual, family, and commu-
nity factors relevant to planning individualized care for
depressed patients and their families, provides health edu-
cation and support on health care needs and resources
that help patients to recover or maintain their health and
independence. The programme establishes the minimum
number of nurse's visits with the patient: in the acute
stage, initially one week after inclusion and then monthly
until remission; in the continuation and maintenance
stage the contacts will be every two/three months. How-
ever, the plan of follow-up visits is individualized depend-
ing on the nature of the patient and the evolution of the
depression. The visits are structured and the patient is pro-
vided with information and education on the illness and
the treatment, including "self-help" activities and health
advice for the patients and their family members. Patients
are provided with specifically designed printed and video-
graphic material. Adherence to the therapeutic plan is sys-
tematically evaluated, the difficulties are identified so that
compliance can be ensured, the possible adverse effects of
the treatment are identified and the clinical evolution of
the patient is evaluated through systematic use of the
Patient Health Questionnaire Depression module (PHQ-
9) [15]. All the information, including the score on the
PHQ-9, is recorded and sent to the responsible doctors so
that they have all the details on the condition and evolu-
tion of the patient and can use them to take decisions on
the treatment (i. e. the need for changes to the treatment,
treating side effects, re-evaluation, consultation with the
psychiatrist, etc.).
To improve the primary care/specialised care interface,
primary care doctors and psychiatrists are able to consult
with each other by telephone or e-mail. Clear criteria for
referrals to the specialised level will be established in
order to improve the quality of referrals. In any case,
whenever patient care is shared between primary and spe-
cialised professionals, responsibility for the treatment and
monitoring of the patient will be clearly established to
prevent any gaps in the care provided. The psychiatrists
are given specific directives emphasising the care process
and the therapeutic options for depressions that are resist-
ant to treatment for the purpose of achieving short-term
remission and preventing long-term relapse.
Control group (usual management)
The doctors in the centres that continue with standard
treatment use their own criteria to attend depressed
patients and are allowed to use any resources they con-
sider appropriate, including referral to the specialised
level. Although the activities involving the detection and
diagnosis of the depression are not included in the evalu-
ation, the doctors in the intervention group could become
more aware through the diagnosis of the depression and
detect cases with a milder depression, introducing an ele-
ment of bias in the inclusion of patients. In order to pre-
vent this, the doctors in the control group are given a
training session on diagnosing and detecting depression,BMC Public Health 2007, 7:253 http://www.biomedcentral.com/1471-2458/7/253
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with the same content as that of the doctors in the inter-
vention group.
Measurements
The results will be monitored and most of the data col-
lected by means of standard questionnaires conducted by
telephone interview by an independent qualified inter-
viewer (a psychologist), who has been trained in tele-
phone interview techniques and in psychiatric nosology.
The interviewer will be unaware of which study group the
patients being interviewed belong to ("blind"). The fol-
low-up interviews shall take place at 0 (baseline), 3, 6 and
12 months after the inclusion of the patient.
Variables and instruments of measurement (See Table 1)
Main outcome variables
In accordance with the aims of this study, the major out-
come variables are response and remission rates and the
measurement of depression severity as a continuous vari-
able.
The severity of depressive symptoms will be measured by
means of the PHQ-9 [15]. This scale is a brief self-reported
diagnosis and a measure of the severity of major depres-
sion (DSM-IV). Several studies support its validity, feasi-
bility, and its capacity to detect changes in depressive
symptoms over time. A validated Spanish version is avail-
able [16]. Published data shows that telephone adminis-
tration of the PHQ-9 is a reliable procedure for assessing
depression [17].
Clinical remission should be the goal of acute treatment
for depression [18]. It is defined as virtually complete
relief of symptoms and return to full functioning, and is
thought of as the optimal goal for the initial phase of
treatment of depression [19]. We have adopted a PHQ-9
score of less than 5 as an operational indicator of remis-
sion [20].
Response is a defined as a 50% reduction in the severity of
the symptoms measured with the PHQ-9 at baseline
[15,19].
To measure health-related quality of life, we will use the
SF-12 Health Questionnaire [21,22] which will provide
two scores: one for physical health and one for mental
health.
Secondary variables and effect modifiers
At baseline:
- The following sociodemographic data will be collected:
sex, age, marital status (single, married/coupled,
divorced/separated or widowed), education (no studies,
primary, lower secondary, upper secondary and univer-
sity), labour status, and social class (I, II, IIIN, IIIM, IV and
V of the British Registrar General's Scale) [23].
- The severity of the physical comorbidity will be meas-
ured using the Duke Severity of Illness Checklist (DUSOI)
[24,25]. This checklist will be filled in by each patient's
Table 1: Study variables
Instrument Assessment area Applied by Time(s) of assessments
Sampling form Age, sex, inclusion/exclusion criteria Primary care physicians Baseline
Sociodemographic data form Age, sex, marital status, educational level, 
labour status, social class
Research interviewer by means of 
telephonic interview
Baseline
Duke Severity of Illness Checklist 
(DUSOI)
Global severity of physical comorbidity Primary care physicians Baseline
PRIME-MD; dysthymia and anxiety 
modules
Common psychiatric comorbidity Primary care physicians Baseline
Patient Health Questionnaire 
(PHQ-9)
Severity of depressive symptoms, 
remission and response rates
Research interviewer by means of 
telephone interview
Baseline, 3, 6 and 12 months
Questionnaire Length of evolution of current 
depressive episode and previous history 
of depression.
Research interviewer by means of 
telephone interview
Baseline
SF-12 Health Survey Health-related quality of life: mental 
health and physical health scores
Research interviewer by means of 
telephone interview
Baseline, 3, 6 and 12 months
Morisky-Green Test Treatment adherence Research interviewer by means of 
telephone interview
Baseline, 3, 6 and 12 months
Use of health resources 
questionnaire
Number of primary care, psychiatric and 
emergency visits, and hospitalisations 
owing to mental health problems
Research interviewer by means of 
telephone interview
3, 6 and 12 months
Satisfaction with the care received Satisfaction of the patient with the 
clinical care got for his depression
Research interviewer by means of 
telephone interview
3, 6 and 12 months
Exploration of the computer 
database of pharmaceutical 
prescription and invoicing
Treatment with antidepressants. Medical 
prescription and consumption by the 
patient.
Research assistant 3, 6 and 12 monthsBMC Public Health 2007, 7:253 http://www.biomedcentral.com/1471-2458/7/253
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family physician. For each diagnosis of a physical nature,
a score is assigned to the symptoms, complications, prog-
nosis and expected response to treatment. The overall
severity of the patient, evaluated from 0 to 100, is
obtained from an equation that gives a greater coefficient
to the main diagnosis and successively lower coefficients
to the other diagnoses.
- To assess the most common psychiatric comorbidity in
depressed patients we will use the dysthymia and anxiety
sections of the Primary Care Evaluation of Mental Disor-
ders (PRIME-MD). This is a 2-stage rapid screening and
interview procedure that can generate a range of diagnoses
of mental disorders according to DSM-IV criteria [26,27].
- We will establish how long the current depressive epi-
sode has been evolving and the previous history of depres-
sion.
In the follow-up interviews, besides measuring depressive
symptomatology with the PHQ-9 and health-related qual-
ity of life with the SF-12 Health Questionnaire:
- Therapeutic compliance will be evaluated by the
Morisky-Green Test [28], the self-report compliance (Hay-
nes-Sackett test) [29], and searching the computer data-
bases for pharmaceutical prescription and invoicing.
- The use of health resources in the evaluated period is
determined by means of interviewing the patient: number
and type of primary care, psychiatric and emergency visits
and hospitalisations for mental health problems.
- The patients' satisfaction with the care received is evalu-
ated using a single item (a Likert scale with five response
options) [30].
Statistical methods
Sample size
To calculate the sample size, we consider the remission
rate at six months as the main result variable.
On the basis of published research data [31], we assume
that this will be 30% in the control group and we aim to
detect a difference of 16% or more between this group and
the intervention group.
Accepting an alpha risk of 0.05 and a beta risk of <0.20 in
a bilateral contrast and assuming a 15% loss in continuing
the treatment, we would need 169 subjects in each group
in a simple random sampling.
To correct this figure for design effect (cluster randomisa-
tion) [13,32] we shall use the formula:
Deff = 1 + (m - 1) × ICC
where Deff: design effect, m: size of clusters and ICC:
intraclass coefficient correlation.
Provisionally assuming an ICC = 0.01 and m = 20, the
Deff will be 1.19. Thus, each group needs to consist of 201
subjects (1.19 × 169 = 201) divided into 10 clusters of 20
patients.
We have no reliable data on the ICC in the sample and in
the variables we studied and we have provisionally used a
prudent figure that will be checked once the data is avail-
able.
Analysis strategy
Randomisation is performed at primary care centre level
and the results of the treatment will be analysed at indi-
vidual patient level [13]. The analyses shall be per intent
to treat.
First we will compare the intervention group with the con-
trol group in order to verify that there are no significant
differences between the two groups (socio-demographic
data, clinical baseline data, etc.). We shall use the mean
(Standard Deviation) in the continuous variables and per-
centages in the categorical variables. For comparisons we
shall use the Student-T test for continuous variables and
the Chi-squared test for categorical variables. Non-para-
metric tests may also be used.
The main variables of the result are the depressive symp-
tomatology (PHQ-9 score), response to treatment (reduc-
tion of 50% or more in the baseline score), remission
(score of <5) and quality of life related to health (SF-12
score) at 3, 6 and 12 months.
Process variables include the number of visits for depres-
sion to the primary care centre, psychiatrist, emergencies
and hospitalisations and the continued use of anti-depres-
sants over 3 months.
We shall use the analysis of the linear mixed models of the
SPSS v.15 statistical package, including the two effects,
fixed and random, to analyse the effect of the continuous
result variables (depression symptomatology [PHQ-9
score], quality of life related to health [SF-12 score]). We
shall analyse the effect of the treatment on the categorical
result variables (response and remission rates) by analys-
ing the general linear models of the SPSS v.15. The ran-
dom effects of these linear models (mixed and general)
provide the structure that enables us to take into account
the effect of randomisation by clusters owing to a poten-
tial lack of independence between observations within the
same centre [33].BMC Public Health 2007, 7:253 http://www.biomedcentral.com/1471-2458/7/253
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Ethical aspects
The design of the study, with the random allocation of pri-
mary care centres to the control group or intervention
group, makes it necessary to obtain informed consent on
two levels: firstly, that of the participating doctors before
they are allocated to the intervention or the control
groups and, secondly, that of the participating patients,
obviously once their centre has been allocated to the cor-
responding group, but before they are aware which group
it is.
Before they give their consent, the patients are provided
with a general overview of the aims and activities of the
study. They are also informed that they will be participat-
ing voluntarily, and that they can choose to drop out at
any time with the guarantee that they will continue to
receive the treatment considered most appropriate by
their doctor. The patients in the control group will receive
the treatment considered most suitable by their doctor,
without limitations.
The information provided to the health professionals is
similar: participation in the study is voluntary and they
can choose to drop out without any negative repercus-
sions for the health or healthcare of their patients if they
consider that continued participation will cause them
harm. The participating professionals will sign a docu-
ment in which they state that they will provide their
patients with information, that they have no conflict of
interest and that participation in the study favours the
interests of their patients.
If the treatment evaluated proves to be effective, patients
in all participating centres, including those in the control
group, are guaranteed continued access to it. In this
respect, the competent management authority will give
their guarantee before the study begins and the centres are
informed of it when their participation is requested.
The Study Protocol was approved by the Research Ethics
Committee of the Jordi Gol i Gurina Primary Care
Research Institute (IDIAP), Barcelona, on March 29, 2006
(ref: P06/16).
Forecast execution dates
Initial recruitment of patients: June 2007
Deadline for recruitment of patients: December 2008
Deadline for period of patient monitoring: December
2009
Publication of the results: March 2010
Discussion
Previous experiences, particularly in the United States,
have shown that the implementation of multifactorial
programmes for the care of depression can give rise to bet-
ter health results [10-12] and at present in several Euro-
pean health systems there are several research projects in
progress that aim to investigate the usefulness of similar
models for handling depression [34-36]. Along these
lines, the objective of the INDI project is to create a pro-
gramme for handling depression that can be applied in
primary health care in the Spanish health system and to
evaluate its effectiveness.
The intervention programme consists of an integral pack-
age of a variety of measures (organization for systematic
and structured handling of depression, case management,
professional training, clinical guidelines and treatment
algorithm, psychological education of the patients) and
one of its qualities is that it has been designed bearing in
mind that it should be applicable to real caring practice so
that, if the evaluation results are favourable, it can be eas-
ily generalized. The programme does not require consid-
erable resources and the main aim of organizational
measures is to optimize existing ones.
One of the innovative aspects, in our ambit, is to define
and promote the role of the nurse in the systematic and
structured handling of depression. The nurse is given the
role of case manager and a central role in organizing the
care of depressed patients. In an attempt to make the most
of the resources available, it was decided to use the nurses
already on the staff of the primary health care centre
instead of contracting external case managers.
One of the limitations of our model is that it focuses on
pharmacological treatment and does not consider psycho-
therapy as a front-line therapeutic option in primary care
because in "real" caring practice in the Spanish health sys-
tem it is a resource that is not often available and,
although it would have been possible to include it in the
context of a research project, it would be difficult to gen-
eralize in practice.
In the design of the clinical trial we opted to randomize
clusters because the intervention to be evaluated is
designed for primary health care centres (e.g. organiza-
tional measures) and health professionals (e.g. medical
education) while the results of these interventions will be
measured in individual patients in the form of health out-
comes. This design makes it possible to avoid the attenu-
ation of the effect of the intervention due to the possible
contamination between study groups if the randomiza-
tion were carried out individually and the patients
assigned to the intervention and control groups wereBMC Public Health 2007, 7:253 http://www.biomedcentral.com/1471-2458/7/253
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attended in the same place and even by the same profes-
sionals.
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